<DOC>
	<DOCNO>NCT00045045</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure positron emission tomography may improve ability detect extent cancer allow doctor plan effective treatment patient testicle cancer . PURPOSE : Diagnostic trial study effectiveness positron emission tomography use fludeoxyglucose F 18 predict relapse patient stage I germ cell tumor testicle .</brief_summary>
	<brief_title>Positron Emission Tomography Detecting Testicle Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess ability fludeoxyglucose F 18 positron emission tomography predict relapse require adjuvant chemotherapy patient high-risk stage I non-seminomatous mixed seminoma/non-seminomatous germ cell tumor testis current management protocol . OUTLINE : This multicenter study . Patients receive fludeoxyglucose F 18 ( FDG ) IV follow 1 hour later positron emission tomography ( PET ) imaging . Patients metastatic disease identify FDG PET imaging may receive adjuvant chemotherapy accord standard clinical practice participate center . Patients metastatic disease identify FDG PET image consider entry MRC-TE08 trial ( randomize trial 2 CT scan frequency surveillance stage I teratoma ) follow accord standard surveillance schedule . Patients metastatic disease follow every 6 month . Patients metastatic disease follow monthly 1 year , every 2 month 1 year , every 3 month 1 year , every 4-6 month thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : Approximately 135 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonseminomatous mixed seminoma/nonseminomatous germ cell tumor testis evidence vascular ( lymphatic venous ) invasion primary specimen Clinical stage I basis clinical examination , chest xray , CT scan chest , abdomen , pelvis Negative postorchidectomy tumor marker ( alphafetoprotein beta human chorionic gonadotropin ) Highrisk disease PATIENT CHARACTERISTICS : Age Any age Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other No evidence active inflammatory infective diseases No disease prior malignancy would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery See Disease Characteristics No 8 week since prior orchidectomy Other No prior positron emission tomography scan</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>stage I malignant testicular germ cell tumor</keyword>
	<keyword>testicular choriocarcinoma</keyword>
	<keyword>testicular choriocarcinoma embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma seminoma</keyword>
	<keyword>testicular choriocarcinoma teratoma</keyword>
	<keyword>testicular choriocarcinoma yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor seminoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma</keyword>
	<keyword>testicular teratoma</keyword>
	<keyword>testicular yolk sac tumor teratoma seminoma</keyword>
	<keyword>testicular yolk sac tumor teratoma</keyword>
	<keyword>testicular yolk sac tumor</keyword>
</DOC>